More men at risk for prostate cancer as a result of less regular screening
the ONA take:
A recent research study examined the potential benefits and potential downsides to the US Preventive Services Task Force (USPSTF) recommendation against regular prostate-specific antigen (PSA) screening for prostate cancer.
Researchers, led by Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, examined the number and distribution of new prostate cancer diagnoses in the United States.
Incident cancers diagnosed from January 2010 through December 2012 were included. The number of new prostate cancer cases diagnosed before and after the USPSTF recommendation were compared against a similar record of colon cancer findings.
The investigators found a drop in the number of prostate cancer diagnoses, a greater than 12% decline, following the USPSTF's PSA screening recommendation.
Prostate cancer diagnoses at all risk levels fell, though new diagnoses of nonlocalized disease did not change. Monthly colon cancer diagnoses remained steady before and after the USPSTF recommendation.
One year after the USPSTF recommendation, diagnoses of new low risk cancers dropped by nearly 38%, which does address the USPSTF intent to reduce overdiagnosis, but the researchers have concerns that the reduction in high- and immediate-risk disease diagnoses could lower chances for early detection and treatment.
pThe team feels that additional research into screening models to maximize early detection for higher risk cancers while keeping overdiagnosis and overtreatment numbers low would be beneficial.
Data from this study were published in The Journal of Urology.
A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Mammograms (Fact Sheet)
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|